期刊
FUTURE ONCOLOGY
卷 7, 期 6, 页码 727-736出版社
FUTURE MEDICINE LTD
DOI: 10.2217/FON.11.49
关键词
AMPK; breast cancer; diabetes mellitus; insulin; metformin
类别
Metformin is an orally available, biguanide derivative that is widely used in the treatment of Type 2 diabetes. Recent preclinical data have demonstrated that it can also act as an anticancer agent by activation of AMPK and subsequent inhibition of mTOR. Metformin is currently being investigated in several Phase II/III clinical trials. This article will review the current evidence for its mechanism of action, efficacy in preclinical and clinical models, and toxicity. Ongoing and planned studies evaluating the impact of metformin on breast cancer outcomes are also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据